Skip to content
10-Q

Quarterly Report

MEDITE CANCER DIAGNOSTICS, INC.

0001654954-18-006862

← back to feed
Filed
Jun 22, 2018 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2018 · Jun 21, 2018 59.37M sh
Operating Cash Flow Q1 2018 · Mar 31, 2018 −$1.64M
Operating Cash Flow Q1 2018 · Mar 31, 2017 −$645K
Long Term Debt Q1 2018 · Mar 31, 2018 $5.16M
Long Term Debt Q1 2018 · Dec 31, 2017 $4.87M
Short Term Debt Q1 2018 · Mar 31, 2018 −$50K
Short Term Debt Q1 2018 · Dec 31, 2017 −$50K
Cash And Equivalents Q1 2018 · Mar 31, 2018 $247K
Cash And Equivalents Q1 2018 · Dec 31, 2017 $490K
Cash And Equivalents Q1 2018 · Dec 31, 2016 $108K
Stockholders Equity Q1 2018 · Mar 31, 2018 $5.94M
Stockholders Equity Q1 2018 · Dec 31, 2017 $5.78M
Current Liabilities Q1 2018 · Mar 31, 2018 $3.8M
Current Liabilities Q1 2018 · Dec 31, 2017 $3.78M
Total Liabilities Q1 2018 · Mar 31, 2018 $10.46M
Total Liabilities Q1 2018 · Dec 31, 2017 $10.18M
Current Assets Q1 2018 · Mar 31, 2018 $3.88M
Current Assets Q1 2018 · Dec 31, 2017 $3.46M
Total Assets Q1 2018 · Mar 31, 2018 $16.41M
Total Assets Q1 2018 · Dec 31, 2017 $15.96M
Sga Expense Q1 2018 · Mar 31, 2018 $919K
Sga Expense Q1 2018 · Mar 31, 2017 $782K
Rd Expense Q1 2018 · Mar 31, 2018 $305K
Rd Expense Q1 2018 · Mar 31, 2017 $425K
Net Income Q1 2018 · Mar 31, 2018 −$1.4M
Net Income Q1 2018 · Mar 31, 2017 −$955K
Operating Income Q1 2018 · Mar 31, 2018 −$960K
Operating Income Q1 2018 · Mar 31, 2017 −$576K
Gross Profit Q1 2018 · Mar 31, 2018 $335K
Gross Profit Q1 2018 · Mar 31, 2017 $680K
Cost Of Revenue Q1 2018 · Mar 31, 2018 $1.17M
Cost Of Revenue Q1 2018 · Mar 31, 2017 $1.21M
Revenue Q1 2018 · Mar 31, 2018 $1.51M
Revenue Q1 2018 · Mar 31, 2017 $1.89M